Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Harvard Business School
McKesson
Moodys
Medtronic

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYPROHEPTADINE HYDROCHLORIDE

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Cyproheptadine Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00066248 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed National Cancer Institute (NCI) Phase 2 2003-06-01 RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment.
NCT00066248 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed University of South Florida Phase 2 2003-06-01 RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment.
NCT00108420 Prazosin Treatment for Combat Trauma PTSD (Post-Traumatic Stress Disorder) Nightmares and Sleep Disturbance Completed VA Office of Research and Development Phase 4 2003-10-01 The purpose of this study is to determine whether prazosin will reduce the incidence of nightmares, sleep disturbance, and overall symptoms in combat trauma-exposed individuals with PTSD.
NCT00286988 Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children Terminated Ortho-McNeil Neurologics, Inc. Phase 4 2006-03-01 The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.
NCT00286988 Topiramate for the Prophylactic Treatment of Cyclic Vomiting Syndrome in Children Terminated Monarch Medical Research Phase 4 2006-03-01 The purpose of this study is to assess the effectiveness, tolerability and safety of oral topiramate for the preventative management of Cyclic Vomiting Syndrome. It is believed that topiramate will decrease the frequency, duration and severity of attacks experienced by children and adolescents with Cyclic Vomiting Syndrome.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cyproheptadine Hydrochloride

Condition Name

Condition Name for Cyproheptadine Hydrochloride
Intervention Trials
Spinal Cord Injury 2
Lymphoma 2
Leukemia 2
Myelodysplastic Syndromes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cyproheptadine Hydrochloride
Intervention Trials
Alcoholism 3
Disease 2
Epidermolysis Bullosa 2
Spinal Cord Injuries 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cyproheptadine Hydrochloride

Trials by Country

Trials by Country for Cyproheptadine Hydrochloride
Location Trials
United States 65
Austria 2
Italy 2
United Kingdom 2
Brazil 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cyproheptadine Hydrochloride
Location Trials
California 5
Illinois 5
Texas 4
Missouri 3
District of Columbia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cyproheptadine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cyproheptadine Hydrochloride
Clinical Trial Phase Trials
Phase 4 6
Phase 3 5
Phase 2 7
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cyproheptadine Hydrochloride
Clinical Trial Phase Trials
Completed 9
Not yet recruiting 3
Recruiting 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cyproheptadine Hydrochloride

Sponsor Name

Sponsor Name for Cyproheptadine Hydrochloride
Sponsor Trials
University of South Florida 3
National Cancer Institute (NCI) 3
Rehabilitation Institute of Chicago 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cyproheptadine Hydrochloride
Sponsor Trials
Other 23
NIH 6
Industry 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Colorcon
Baxter
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.